Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUMP study of ruxolitinib in Myelofibrosis
NCT01493414Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of ruxolitinib in myelofibrosis (MF), sponsored by Novartis. Started Aug 2011; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01493414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01493414.